Haemonetics Corporation

6 days ago · zacks.com

Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

12 days ago · globenewswire.com

—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients' individual needs and preferences—

14 days ago · prnewswire.com

BOSTON, Oct. 19, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics' portfolio of clinically-differentiated large-bore closure devices for structural heart and endovascular procedures in the U.S., following the company's acquisition of Vivasure Medical Limited in January 2026.

17 days ago · zacks.com

HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.

20 days ago · zacks.com

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

24 days ago · zacks.com

Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

25 days ago · gurufocus.com

On October 08, 2026, Haemonetics Corp (HAE) shares experienced a significant rise of 17.5%, bringing the current price to $119.47. The stock has seen remarkable

25 days ago · globenewswire.com

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of HAE attacks in adolescents and adults have been published in  The Lancet (Journal Impact Factor: 109.0).

25 days ago · proactiveinvestors.com

Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable for moving its US plasma collection centers onto the company's devices. CSL Limited (ASX:CSL), the Australian biotechnology company, expects to finish rolling out Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of 2027.

25 days ago · barrons.com

CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.